Synthesis, Characterization, Cytotoxic Activity, and Interactions with CT-DNA and BSA of Cationic Ruthenium(II) Complexes Containing Dppm and Quinoline Carboxylates

Table 2

Inhibitory activity of ruthenium complexes and cisplatin against normal and tumor cell lines for 24 h incubation, expressed as IC₅₀, µg·mL⁻¹ (µM) and selectivity index (SI).

	Cell line
				GM07492	SI^1	SI^2	SI^3
cis-[RuCl2(dppm)2]	102 ± 26 (108  ±  26)	180 ± 13 (191  ±  13)	126 ± 10 (134  ±  10)	62 ± 4 (66  ±  4)	0.61	0.34	0.49
1	11.8 ± 0.7 (10.1  ±  0.6)	14.2 ± 0.6 (12.1  ±  0.5)	13 ± 2 (11  ±  2)	11 ± 1 (10  ±  1)	0.93	0.77	0.85
2	31 ± 6 (26  ±  5)	162 ± 14 (135  ±  11)	44 ± 3 (36  ±  2)	45 ± 1 (37  ±  1)	1.45	0.28	1.02
	1.9 ± 0.2 (6.3  ±  0.7)	10 ± 1 (34  ±  4)	7 ± 1 (22  ±  4)	8 ± 1 (26  ±  3)	4.21	0.80	1.14

hepatocellular carcinoma, breast adenocarcinoma, glioblastoma, human lung fibroblasts, and drug. SI¹ = IC₅₀ GM07492A/IC₅₀ HepG2; SI² = IC₅₀ GM07492A/IC₅₀ MCF-7; SI³ = IC₅₀ GM07492A/IC₅₀ MO59J.